Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Sientra (SIEN) yesterday and set a price target of $6.00. The company’s shares closed last Monday at $4.75.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 10.4% and a 54.8% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sientra with a $6.67 average price target, representing a 44.7% upside. In a report issued on October 28, Maxim Group also assigned a Buy rating to the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.71 and a one-year low of $1.00. Currently, Sientra has an average volume of 719.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini in August 29, 2003 and is headquartered in Santa Barbara, CA.
